Results 51 to 60 of about 1,999,691 (336)

DoctorEye: A clinically driven multifunctional platform, for accurate processing of tumors in medical images [PDF]

, 2010
Copyright @ Skounakis et al.This paper presents a novel, open access interactive platform for 3D medical image analysis, simulation and visualization, focusing in oncology images.
Alexandros Roniotis, Christina Farmaki, Emmanouil Skounakis, Gonzalez R C, Kass M, Konstantinos Banitsas, Konstantinos Marias, Norbert Graf, Peng H, Perona P, Vangelis Sakkalis, Warfield K   +11 more
core   +2 more sources

Goodbye flat lymphoma biology

FEBS Letters, EarlyView.
Three‐dimensional (3D) biological systems have become key tools in lymphoma research, offering reliable in vitro and ex vivo platforms to explore pathogenesis and support precision medicine. This review highlights current 3D non‐Hodgkin lymphoma models, detailing their features, advantages, and limitations, and provides a broad perspective on future ...
Carla Faria, Cèlia Dobaño‐López, Patricia Pérez‐Galán, Christine Bezombes   +3 more
wiley   +1 more source

Ethical hurdles in the prioritization of oncology care [PDF]

, 2016
With finite resources, healthcare payers must make difficult choices regarding spending and the ethical distribution of funds. Here, we describe some of the ethical issues surrounding inequity in healthcare in nine major European countries, using cancer ...
Capri, Stefano, Castanier, Jean-Claude, Cunningham, David, de Groot, Folkert, Flamion, Bruno, Flume, Mathias, Herholz, Harald, Levin, Lars-Åke, Rupprecht, Christoph J., Shalet, Natalie, Solà-Morales, Oriol, Walker, Andrew, Wong, Olivier   +12 more
core   +1 more source

Biosimilars in oncology

ESMO Open, 2018
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (Young Oncologist Committee member) talks to Josep Tabernero (ESMO President
openaire   +4 more sources

The anabolic steroid stanozolol is a potent inhibitor of human MutT homolog 1

FEBS Letters, EarlyView.
MutT homolog 1 (MTH1) is a member of the NUDIX superfamily of enzymes and is an anticancer drug target. We show that stanozolol (Stz), an anabolic steroid, is an unexpected nanomolar inhibitor of MTH1. The X‐ray crystal structure of the human MTH1–Stz complex reveals a unique binding scaffold that could be utilized for future inhibitor development ...
Emma Scaletti Hutchinson, Robert Gustafsson Westergren, Ingrid Almlöf, Ann‐Sofie Jemth, Martin Scobie, Ulrika Warpman Berglund, Thomas Helleday, Pål Stenmark   +7 more
wiley   +1 more source

Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer

Current Therapeutic Research, 2022
: Background: CRC is the second and third most common cancer in women and men, respectively. The national comprehensive cancer network guidelines recommend oxaliplatin-based chemotherapy as a preferred regimen for patients with advanced or metastatic ...
Farhad Shahi, Mojtaba Gorji, Assistant Professor of Pediatric Oncology, Mehrdad Payandeh, Assistant Professor of Hematology & Oncology, Hamid Rezvani, Associate Professor of Hematology & Oncology, Mohammad Vaezi, Associate Professor of Hematology & Oncology, Sharareh Seifi, Assistant Professor of Hematology & Oncology, Alireza Baari, Post doctoral fellowship, Reza Khalili-Dizaji, Post doctoral fellowship, Seyed Mehdi Hashemi, Associate Professor of Hematology & Oncology, Saeid Salimi, post doctoral fellowship, Hosein Kamranzadeh, Associate Professor of Hematology & Oncology, Babak Shazad, Post doctoral fellowship, Sina Salari, Associate Professor of Hematology & Oncology, Davoud Oulad Dameshghi, Assistant Professor of Hematology & Oncology, Mehdi Sarkheil, Post doctoral fellowship, Mehrzad Mirzania, Associate Professor of Hematology & Oncology, Nassim Anjidani, Pharm. D.   +16 more
doaj  

Improved therapeutic index of an acidic pH-selective antibody

mAbs, 2022
Although therapeutically efficacious, ipilimumab can exhibit dose-limiting toxicity that prevents maximal efficacious clinical outcomes and can lead to discontinuation of treatment.
Peter S. Lee, Katherine G. MacDonald, Evan Massi, Pamela V. Chew, Christine Bee, Padma Perkins, Bryant Chau, Kent Thudium, Jack Lohre, Pradyot Nandi, Ekaterina G. Deyanova, Ishita Barman, Olafur Gudmundsson, Gavin Dollinger, Tim Sproul, John J. Engelhardt, Pavel Strop, Arvind Rajpal   +17 more
doaj   +1 more source

Medical oncology patients' preferences with regard to health care: development of a patient-driven questionnaire [PDF]

, 2009
BACKGROUND: To improve quality of care for cancer patients, it is important to have an insight on the patient's view on health care and on their specific wishes, needs and preferences, without restriction and without influence of researchers and health ...
Avis, Bredart, Clark, Committee on Quality of Health Care in America IoM, Crawford, de Kok, Department of Health, Gesell, Gilmore, Glaser, Gourdji, Groenewegen, Kitzinger, Kleeberg, Morgan, Nunnally, Polit, Richards, Richardson, Sandoval, Sandoval, Sixma, Skarstein, Tamburini, Tamburini, The Advisory Board Company, Oncology Roundtable, Turhal, van Campen, Wiggers   +28 more
core   +3 more sources

Zebrafish in oncology

Aging, 2013
Novel high-throughput technologies generate an unprecedented amount of data, which present a challenge for oncologists aiming to provide personalized treatment. Progress in genetic engineering and xenotransplantation in conjunction with live imaging could establish the zebrafish as one of the most versatile animal models for cancer research.
Barriuso, Jorge, Nagaraju, Raghavendar, Hurlstone, Adam   +2 more
openaire   +3 more sources

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source